



SUPPLEMENTARY FIG. S5. The ABR and DPOAE thresholds of heparin binding–epidermal growth factor (HB-EGF)-treated ears compared with control (16 weeks). Figure shows the (a) ABR and (b) DPOAE thresholds measured at 16 weeks in ears perforated and injected with the polymer hydrogel loaded with HB-EGF at 50 $\mu\text{g}/\text{mL}$ ($n=13$), 10 times the effective dose, compared with control ears, which were injected with the polymer hydrogel only ($n=13$). There were no differences between groups demonstrating a lack of ototoxicity of HB-EGF in the mouse model.